A phase 2 study of vatalanib in metastatic melanoma patients.

Abstract

BACKGROUND:

A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma.

METHODS:

Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0-2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming's single stage design.

RESULTS:

Tumour control rate (CR+PR+SD) was 35% at 16 weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8 months (95% CI 1.8-3.7 months) and median overall survival was 6.5 months (95% CI 3.9-10.2 months).

CONCLUSION:

Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing.

• Authors: Natalie Cook, Bristi Basu, Swethajit Biswas, Paula Kareclas, Colette Mann, Cheryl Palmer, Anne Thomas, Steve Nicholson, Bruno Morgan, David Lomas, Bhawna Sirohi, Adrian P Mander, Mark Middleton, Pippa G Corrie
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 46 Issue 15 Pg. 2671-3 (Oct 2010) ISSN: 1879-0852 [Electronic] England
• PMID: 20800475 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Phthalazines
• Pyridines
• vatalanib

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (administration & dosage)
• Female
• Humans
• Male
• Melanoma (drug therapy, secondary)
• Middle Aged
• Phthalazines (administration & dosage)
• Pyridines (administration & dosage)
• Skin Neoplasms (drug therapy)
• Treatment Outcome
• Young Adult